276 results on '"Jiang, Yixing"'
Search Results
52. Impact of Genetic Targets on Cancer Therapy in Esophagogastric Cancer
53. Inhibition of anchorage-independent growth and lung metastasis of A549 lung carcinoma cells by IκBβ
54. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor
55. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma
56. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma
57. Tyrosine Kinase Update: Role and Response in Cancer Therapy
58. TLSurv
59. Abstract CT114: Pharmacokinetic analysis of navitoclax in combination with sorafenib in patients with relapsed or refractory solid organ tumors
60. Abstract 874: Adoptive transfer of cytotoxic lymphocytes generated by engineered human dendritic cells for AML treatment
61. Secret Sharing Simultaneously in Internet of Things
62. Cancer Survivorship: A New Challenge for Surgical and Medical Oncologists
63. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment
64. Assessment of K-ras mutation: A step toward personalized medicine for patients with colorectal cancer
65. Upper gastrointestinal tumors: current status and future perspectives
66. Cloning and expression of chicken protein tyrosine phosphatase gamma
67. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer
68. Lung-Specific Expression of Dominant-Negative Mutant p53 in Transgenic Mice Increases Spontaneous and Benzo(a)pyrene-Induced Lung Cancer
69. Molecular and Genetic Aspects of Lung Cancer
70. Temporary remission of advanced hepatocellular carcinoma in a patient treated with sorafenib therapy alone - A case report and literature review
71. B-106 Development of anti-tumor cytotoxic lymphocytes using engineered human primary blood dendritic cells
72. The use of nanoparticulates to treat breast cancer
73. Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma.
74. DNAJB1-PRKACAfusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma
75. Leptomeningeal Carcinomatosis as the Only Manifestation of Disease in Recurrent Gastroesophageal Cancers
76. Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer “The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease”
77. Advances in the Pharmacologic Treatment of Hepatocellular Carcinoma
78. Advanced Gastric Cancer: A Disease of Diverse Clinical Biology
79. Adjuvant and Preoperative Therapy for Localized Gastric Cancer
80. A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent
81. An integrated development environment for faster feature engineering
82. A phase I trial of of cixutumumab (C) (IMC-A12) and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC).
83. A phase I trial of cixutumumab (C) (IMC-A12) and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC).
84. Altered Sphingolipid Metabolism in Patients with Metastatic Pancreatic Cancer
85. Anal margin cancer
86. ABT-888 (veliparib) in combination with weekly carboplatin and paclitaxel in advanced solid tumors.
87. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of intravenous dimethane sulfonate (DMS612, NSC 281612) in advanced malignancies.
88. A phase I study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies.
89. A phase I study of chronically dosed, single-agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer (BRCA-wt).
90. Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation
91. Guidelines for managing gastric cancer
92. Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer
93. Identifying Circulating Tumor Stem Cells That Matter: The Key to Prognostication and Therapeutic Targeting
94. Tyrosine Kinase Update: Role and Response in Cancer Therapy
95. Multidisciplinary Management of Early and Locally Advanced Esophageal Cancer
96. Multidisciplinary management of gastric cancer
97. Multimodality Approaches to Localized Gastric Cancer
98. Anal Carcinoma Therapy: Can We Improve on 5-Fluorouracil/Mitomycin/Radiotherapy?
99. The role of CD11c+ hepatic dendritic cells in immue tolerance to hepatocellular carcinoma (41.48)
100. Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.